ArticleJournal of applied genetics2025
Genetic variations in NFKB1 signaling molecules: implications for acute lymphoblastic leukemia in Saudi Arabia.
Article in Journal of applied genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling regulates immune responses and tumorigenesis. Variations in NF-κB pathway genes may alter susceptibility to acute lymphoblastic leukemia (ALL). To evaluate associations between selected NFKB1 and NFKBIA polymorphisms and ALL risk in a Saudi population. We genotyped NFKB1 (rs93059, rs1287, rs1801) and NFKBIA (rs1050851, rs1957106, rs3138054) in 150 ALL patients and 115 matched controls using TaqMan® assays. Associations were assessed under multiple genetic models, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. The NFKB1 rs93059 A allele was associated with reduced ALL risk (OR = 0.68; 95% CI: 0.48-0.97; p = 0.03), with the AA genotype showing protection in codominant (p = 0.03) and recessive (p = 0.02) models. For NFKB1 rs1287, the AA genotype increased risk (OR = 2.75; 95% CI: 1.14-6.62; p = 0.02) in the codominant model. The NFKB1 rs1801 C allele was enriched in patients (OR = 1.54; 95% CI: 1.04-2.23; p = 0.01). No significant associations were observed for NFKBIA variants after multiple-testing correction. NFKB1 rs93059 and rs1801 may influence ALL susceptibility in the Saudi population, underscoring the potential contribution of NF-κB pathway variants to leukemia risk. Functional analyses are warranted to clarify underlying mechanisms.
Indexed as
Identifiers
41205109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.